

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:	BRÖGMANN, et al.	Confirmation No.:	1883
Serial No.:	10/510,673	Art Unit:	1615
Filed:	May 23, 2005	Examiner:	Helm, Coralynne E.
For:	MATRIX FOR SUSTAINED, INVARIANT AND INDEPENDENT RELEASE OF ACTIVE COMPOUNDS	Attorney Docket No.:	Y2428-00163

TERMINAL DISCLAIMER UNDER 37 C.F.R. § 1.321(c)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Your Petitioner, Douglas Docherty represents that he holds the position of Director, of Euro-Celtique S.A., the assignee of the entire 100% right, title and interest in and to United States Patent Application No. 10/510,674, filed on May 23, 2005, entitled, "Pharmaceutical Preparation Containing Oxycodone And Naloxone", and the above-identified application by virtue of an assignment from Euro-Celtique S.A. submitted herewith. Euro-Celtique S.A. was the prior assignee of United States Patent Application No. 10/510,674 by virtue of an assignment from the inventors recorded in the United States Patent and Trademark Office on August 18, 2005, at Reel 016648, Frame 0643.

Petitioner hereby disclaims the terminal part of any patent granted on the above identified application which would extend beyond the expiration date of U.S. Patent Application No. 10/510,674, which published on November 3, 2005, and any patent which issues based upon U.S. patent application serial no. 10/510,674 and hereby agrees that any patent so granted on the above-identified application shall be enforceable only for and during such period that the legal title to said patent shall be the same as the legal title to U.S. Patent Application No. 10/510,674, and any patent which issues based upon U.S. patent application serial no. 10/510,674.

Petitioner further agrees that this agreement is to run with any patent granted on the above identified application and is to be binding upon the grantee, its successors, and assigns.

Petitioner does not disclaim any terminal part of any patent granted on the above-identified application prior to the expiration date of the full statutory term of U.S. Patent Application No. 10/510,674, and any patent which issues based upon U.S. Patent Application No. 10/510,674, in the event that said patent later expires for failure to pay a maintenance fee, is held unenforceable, is found invalid, is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. 1.321(a), has all claims canceled by a reexamination certificate, or is otherwise terminated prior to the expiration of its full statutory term, except for the separation of legal title stated above.

Petitioner hereby confirms that he has reviewed the assignment and, to the best of his knowledge and belief, title is in the assignee seeking to take action in this matter and that he is empowered to act on behalf of Euro-Celtique S.A.

Petitioner hereby declares that all statements made herein of his own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Signed this 30 day of October, 2009.

EURO-CELTIQUE S.A.

By: 
Name: Douglas Docherty
Title: Director